[1] SIU A L. Screening for breast cancer: U.S. preventive services task forcere commendation statement[J]. Ann Int Med, 2016, 164 (4) :279-296. [2] TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. Ca-Cancer J Clin, 2015, 65(2): 87-108. [3] 孙玉巧,周涛,李云涛,等. 完全植入式静脉输液港的临床应用[J]. 中华外科杂志,2014,52(8): 608-611. [4] GURKAN S, SEBER S, GUR O, et a1. Retrospective evaluation of totally implantable venous access port devices: early and late complications[J]. J BUON, 2015, 20(1): 338-345. [5] 宋仲学,刘健,张佩佩, 等.彩色多普勒引导下完全埋入式静脉输液港颈内静脉植入术的有效性和安全性[J]. 现代肿瘤医学,2021,29(14):2506-2509. [6] 中心静脉通路上海协作组. 完全植入式输液港上海专家共识[J]. 介入放射学杂志, 2015, 24(12): 1029-1033. [7] ALMASI-SPERLING V, HIEBER S, LERMANN J, et al. Femoralplacement of totally implantable venous access ports in patients with bilateral breast cancer[J]. Geburtshilfe Frauenheilkd, 2016(76):53-58. [8] WILDGRUBER M, BORGMEYER S, HALLER B, et al. Short-term and long-term outcome of radiological-guided insertionof central venous access port devices implanted at the forearm: a retrospective monocenter analysis in 1704 patients[J]. Eur Radiol, 2015,(25):606-616. [9] 毛美芬, 徐亚文, 高雪娟, 等. 乳腺癌化疗患者输液港相关血栓形成的影响因素[J]. 护理学杂志, 2019, 34(1): 33-35. [10] CAERS J, FONTAINE C, VINH-HUNG V, et al. Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports[J]. Support CareCancer, 2005, 13(5): 325-331. [11] 张进泓,罗凤.3380例乳腺癌患者放置完全植入式静脉输液港化疗的并发症分析[J]. 中华乳腺病杂志(电子版),2019,13(6):350-355. [12] WOOD S C, TANG X, TESFAMARIAM B. Paclitaxel potentiates in flammatory cytokine-induced prothrommbotic molecules in endothelial cells[J]. J Cardiovasc Pharmacol, 2010, 55(3): 276-285. [13] SCHROTH W,WINTER S,BUTTNER F,et al. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative /progesterone receptor-positive invasive breast cancer phenotype[J]. Breast Cancer Res Treat,2016, 155(1) : 85-97. [14] 韩晶, 王培军, 汤如勇,等. HER-2基因在乳腺癌中的表达及其与雌激素受体亚型的关系[J]. 第二军医大学学报, 2006, 27(11): 1268-1269. [15] 蒋凤莲,杨伟洪,黄文宇.乳腺癌患者血浆D-二聚体水平与乳腺癌组织中Ki-67表达的相关性[J]. 中国实用医药,2021,16(13):24-27. |